Introduction
============

Optic nerve damage and visual impairment caused by glaucoma as a global health problem, is the second most common cause of blindness in the world, affecting 66.8 million people and causing bilateral blindness in 6.7 million people. Besides, as the population ages, its incidence shows a further upward trend ([@b1-etm-0-0-8182],[@b2-etm-0-0-8182]). There are two types of glaucoma: angle-closure glaucoma and open-angle glaucoma. Cataract is a major cause of angle-closure glaucoma, because intumescent cataract can lead to acute closure of patient\'s angle, then induce glaucoma, which is a very common phenomenon in clinic ([@b3-etm-0-0-8182],[@b4-etm-0-0-8182]). Surgery is the main treatment for cataract with glaucoma.

To date, the most commonly used operating methods in clinic are trabeculectomy, phacoemulsification and intraocular lens implantation, among which trabeculectomy is the most classic one ([@b5-etm-0-0-8182]). However, trabeculectomy can lead to a high incidence of postoperative complications despite the continuous improvement of trabeculectomy technique and the combination with lens removal, which could effectively prevent the peripheral iridocorneal adhesions. Once the adhesions develop, they remain and worsen the disease condition ([@b6-etm-0-0-8182],[@b7-etm-0-0-8182]). In recent years, clinicians have increasingly paid attention to and applied phacoemulsification and intraocular lens implantation combined with goniosynechialysis for the treatment of cataract with angle-closure glaucoma. Studies have reported that phacoemulsification and intraocular lens implantation combined with goniosynechialysis can effectively reduce intraocular pressure, without developing complications that traditional glaucoma surgery brings, such as low intraocular pressure, macular edema or recurrent angle closure ([@b8-etm-0-0-8182],[@b9-etm-0-0-8182]). However, traditional phacoemulsification and intraocular lens implantation also have some shortcomings. For patients with complicated cataract, the high ultrasonic energy of traditional phacoemulsification largely damages the corneal endothelium ([@b10-etm-0-0-8182]). Modified phacoemulsification (lower ultrasonic energy) and intraocular lens implantation have now achieved certain efficacy in patients with cataract and high myopia ([@b11-etm-0-0-8182]).

The present study retrospectively analyzed the application of modified phacoemulsification and intraocular lens implantation combined with goniosynechialysis for the treatment of cataract with glaucoma, to evaluate the therapeutic effect and safety, and to provide further guidance for clinical treatment.

Patients and methods
====================

### Subjects

Data of 304 cases of cataract with glaucoma admitted to The Third Affiliated Hospital of Chongqing Medical University from April 2017 to September 2018 were retrospectively analyzed. Patients were aged 30--70 years. They were enrolled into two groups according to different treatment methods: 179 patients treated with modified phacoemulsification and intraocular lens implantation combined with goniosynechialysis were included in the study group; 125 patients treated with phacoemulsification and intraocular lens implantation combined with goniosynechialysis were included in the control group. This study was approved by the Ethics Committee of The Third Affiliated Hospital of Chongqing Medical University, and the informed consent form was obtained from all the patients and their families by informing them via telephone or letter.

Patients were eligible if they had glaucoma that met the diagnostic criteria of the Expert Consensus on Diagnosis and Treatment of Primary Glaucoma (2014) developed by the Ophthalmology Branch, Chinese Medical Association ([@b12-etm-0-0-8182]); had acute attack; had only one eye involved; had complete clinical data; had no past medical history of tumor, glaucoma, or any eye surgery including visual correction. Patients were excluded if they had open angle glaucoma, chronic angle-closure glaucoma, or secondary glaucoma; had surgical contraindications; had abnormal bleeding, other eye diseases, diabetes, systemic inflammatory response, autoimmune diseases, or serious defects in cardiopulmonary function; had incomplete medical records; were pregnant or in lactation.

### Therapeutic methods

All patients were given pilocarpine nitrate eye drops 1 h before surgery to reduce intraocular pressure. If necessary, 250 ml of 20% mannitol was given to reduce intraocular pressure, which was maintained at ≤25 mmHg.

In the control group, phacoemulsification and intraocular lens implantation combined with goniosynechialysis were performed. After topical and peribulbar anesthesia with oxybuprocaine hydrochloride and lidocaine, a tunnel incision was made along the transparent corneal edge at direction of 11 o\'clock. Then, 0.2 ml of viscoelastic agent was injected into the anterior chamber to perform continuous curvilinear capsulorhexis. The physiological saline was used for hydrodissection, and the phacoemulsification apparatus was used to emulsify the lens nucleus, and the perfusion/resorption system was used to remove the residual cortex. Next, 0.3 ml of viscoelastic agent was injected to enlarge the angle. The intraocular lens in appropriate size was placed in the capsule before the goniosynechialysis was conducted. The root of the iris was pressed backward 360° along the angle with the use of sodium hyaluronate, and the adhesions of the angle were separated twice. After that, the residue such as viscoelastic agent was extracted, the incision of transparent corneal was hydrated, and carefully observed for aqueous humor leakage. After injection of 2 mg of dexamethasone under the bulbar conjunctiva, the eye was dressed with sterile gauze.

In the research group, modified phacoemulsification and intraocular lens implantation combined with goniosynechialysis were performed. After topical and peribulbar anesthesia with oxybuprocaine hydrochloride and lidocaine, a tunnel incision was made along the transparent corneal edge at direction of 11 o\'clock. Then, 0.2 ml of viscoelastic agent was injected into the anterior chamber to perform continuous curvilinear capsulorhexis. Physiological saline was used for hydrodissection, and the phacoemulsification apparatus emulsified the lens nucleus in a mode of high negative pressure, low energy, and low discharge to assist the nucleus fragmentation. The chopper was placed in the appropriate site for nucleus fragmentation. The perfusion/resorption system was then used to remove the residual cortex. Next, 0.3 ml of viscoelastic agent was injected to enlarge the angle. An intraocular lens of appropriate size was placed in the capsule before the goniosynechialysis was conducted. The root of the iris was pressed backward 360° along the angle with the use of sodium hyaluronate, and the adhesions of the angle were separated twice. After that, the residue such as viscoelastic agent was extracted, and the incision of transparent corneal was hydrated, and the aqueous humor leakage carefully observed. After injection of 2 mg of dexamethasone under the bulbar conjunctiva, the eye was dressed with sterile gauze.

### Outcome measures

All patients were followed 6 months after surgery. The visual acuity, intraocular pressure, central anterior chamber depth, angle-opening distance, and peripheral iridocorneal adhesions were observed before and after surgery. The incidence of complications was compared between the two groups.

### Statistical analyses

SPSS19.0 (Asia Analytics Formerly SPSS China) was used for statistical processing. The count data were expressed as rate, which was compared using χ^2^ test, and the comparison between before and after treatment within group was performed using McNemar\'s test. The measurement data, which were expressed as mean ± standard deviation, compared between two groups using independent sample t-test, and compared between before and after treatment within group using paired t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Baseline data

In the control group, there were 125 patients, including 72 males (57.60%) and 53 females (42.40%), aged 52.8±8.5 years. In the research group, there were 179 patients, including 107 males (59.78%) and 72 females (40.22%), aged 54.6±9.1 years. There was no significant difference in sex, age, Lens Opacities Classification System II grading and Scheie classification between the two groups (all P\>0.05) ([Table I](#tI-etm-0-0-8182){ref-type="table"}).

### Comparison of changes in visual acuity

Before surgery, the visual acuity was not statistically different between the two groups (P\>0.05), while after treatment, there was a statistically significant difference in the visual acuity between the two groups (P\<0.05). Further McNemar\'s test showed that there were more patients with visual acuity of 0.2--0.4, and \>0.4 in the research group than in the control group (both P\<0.05) ([Table II](#tII-etm-0-0-8182){ref-type="table"}).

### Comparison of changes in intraocular pressure

Before surgery, there was no significant difference in the intraocular pressure between the two groups (P\>0.05). After surgery, the intraocular pressure was decreased in both groups (both P\<0.001) ([Fig. 1](#f1-etm-0-0-8182){ref-type="fig"}).

### Comparison of changes in central anterior chamber depth

Before surgery, there was no significant difference in the central anterior chamber depth between the two groups (P\>0.05). After surgery, the central anterior chamber depth of the two groups both increased to different degrees (both P\<0.001) ([Fig. 2](#f2-etm-0-0-8182){ref-type="fig"}).

### Comparison of changes in angle-opening distance

Before surgery, there was no significant difference in the angle-opening distance between the two groups (P\>0.05). After surgery, the angle-opening distance of the two groups both increased to different degrees (both P\<0.001) ([Fig. 3](#f3-etm-0-0-8182){ref-type="fig"}).

### Comparison of changes in peripheral iridocorneal adhesions

The peripheral iridocorneal adhesions were reduced after surgery as compared with before surgery in both groups, while there was no difference in preoperative or postoperative peripheral iridocorneal adhesions between the two groups (both P\>0.05) ([Table III](#tIII-etm-0-0-8182){ref-type="table"}).

### Comparison of complications

The total incidence of complications in the research group was significantly lower than that in the control group (P\<0.05). Moreover, the incidence of corneal edema and anterior chamber inflammation was significantly lower in the research group than in the control group (both P\<0.05). However, there was no significant difference in the incidence of hyphema and fibrinous exudate in the anterior chamber between the two groups (both P\>0.05) ([Table IV](#tIV-etm-0-0-8182){ref-type="table"}).

Discussion
==========

Angle-closure glaucoma is predominantly caused by the blocking of the aqueous humor outflow due to the closure of the angle, resulting in increased intraocular pressure, thereby causing optic nerve damage and progressive visual impairment. It is estimated that the number of glaucoma patients worldwide will reach 79.6 million by 2020 ([@b13-etm-0-0-8182],[@b14-etm-0-0-8182]). The main principle of clinical treatment for angle-closure glaucoma is to relieve the closure of the angle and the adhesions. Goniosynechialysis is a surgical method that removes the peripheral iridocorneal adhesions from the angle wall to reconstruct the function of the trabeculae, which can effectively reduce the intraocular pressure and peripheral iridocorneal adhesions in patients with angle-closure glaucoma ([@b15-etm-0-0-8182],[@b16-etm-0-0-8182]). Furthermore, in patients with glaucoma caused by cataract, the treatment should also give consideration to glaucoma. It has been reported that combined surgeries were more effective than surgery for cataract alone in reducing intraocular pressure and could reduce the administration of postoperative anti-glaucoma drugs ([@b17-etm-0-0-8182]).

The two groups in this study were comparable as there was no significant difference in the baseline data between the two groups. The results of this study showed that the improvement of visual acuity in the research group was more significant than that in the control group, while the improvement of intraocular pressure, central anterior chamber depth, open-angle distance, and the iridocorneal adhesions were not significantly different between the two groups. However, the research group showed lower incidence of complications than the control group, mainly including lower incidence of corneal edema and anterior chamber inflammation. The reduction of phacoemulsification energy in cataract surgery can decrease the postoperative corneal swelling and endothelial cell loss ([@b18-etm-0-0-8182]). Jacob ([@b19-etm-0-0-8182]) reported the advantages of assisted nucleus fragmentation in phacoemulsification. The advantages were effective reduction of ultrasound energy, endothelial damage, and eye stress. Ianchulev *et al* ([@b20-etm-0-0-8182]) also reported lower rate of endothelial cell loss caused by combined nucleus fragmentation than by phacoemulsification alone. However, the present study lacks data on endothelial cell detection as this is a retrospective analysis, so further prospective studies or randomized controlled studies to supplement our results are required.

In addition, the intraocular pressure after goniosynechialysis depends on the function of the trabecular meshwork. Long-term peripheral iridocorneal adhesions may cause irreversible damage on the trabecular meshwork. Therefore, the duration of peripheral iridocorneal adhesions must be considered before goniosynechialysis ([@b16-etm-0-0-8182],[@b21-etm-0-0-8182]). This was also confirmed by Lee *et al* ([@b22-etm-0-0-8182]) who reported similar therapeutic effects of phacoemulsification and intraocular lens implantation combined with goniosynechialysis and of phacoemulsification and intraocular lens implantation alone in patients with primary angle-closure glaucoma and favorable preoperative intraocular pressure. Different preoperative intraocular pressure may be the reason for the different therapeutic effects of goniosynechialysis in some studies. There are some limitations in this study. Retrospective analysis can inevitably result in some selection bias. Therefore, the results of this study still need further confirmation by clinical randomized controlled trials.

In summary, modified phacoemulsification and intraocular lens implantation combined with goniosynechialysis for the treatment of cataract with glaucoma can better improve the visual acuity, and reduce corneal edema and anterior chamber inflammation. Since the intraocular pressure after goniosynechialysis depends on the function of the trabecular meshwork, the possible duration of peripheral iridocorneal adhesions should be considered before goniosynechialysis, so as to improve the iridocorneal adhesions.
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###### 

Baseline data.

  Factors                           Control group (n=125)   Research group (n=179)   χ^2^/t value   P-value
  --------------------------------- ----------------------- ------------------------ -------------- ---------
  Sex (n, %)                                                                         0.144          0.704
    Male                            72 (57.60)              107 (59.78)                             
    Female                          53 (42.40)              72 (40.22)                              
  Age (year)                        52.8±8.5                54.6±9.1                 1.789          0.075
  LOCS II grading (n, %)                                                             1.125          0.570
    II                              37 (29.60)              47 (26.26)                              
    III                             74 (59.20)              105 (58.66)                             
    IV                              14 (11.20)              27 (15.08)                              
  Diseased eye (n, %)                                                                0.712          0.399
    Left eye                        62 (49.60)              80 (44.69)                              
    Right eye                       63 (50.40)              99 (55.31)                              
  Scheie\'s classification (n, %)                                                    0.282          0.869
    N II                            25 (20.00)              40 (22.35)                              
    N III                           34 (27.20)              49 (27.37)                              
    N IV                            66 (52.80)              90 (50.28)                              

LOCS, Lens Opacities Classification System.

###### 

Changes in visual acuity.

  Parameters         Control group (n=125)   Research group (n=179)   χ^2^ value   P-value
  ------------------ ----------------------- ------------------------ ------------ ---------
  Before treatment                                                    0.928        0.629
    \<0.1            44 (35.20)              66 (36.87)                            
    0.1--0.2         60 (48.00)              90 (50.28)                            
    0.2--0.4         21 (16.80)              23 (12.85)                            
    \>0.4            0 (0.00)                0 (0.00)                              
  After treatment                                                     11.192       0.011
    \<0.1            11 (8.80)               7 (3.91)                              
    0.1--0.2         41 (32.80)              46 (25.70)                            
    0.2--0.4         36 (28.80)              61 (34.08)                            
    \> 0.4           37 (29.60)              65 (36.31)                            
  χ^2^ value         64.322                  144.111                               
  P-value            \<0.001                 \<0.001                               

###### 

Changes in peripheral iridocorneal adhesions.

  Parameters         Control group (n=125)   Research group (n=179)   χ^2^ value   P-value
  ------------------ ----------------------- ------------------------ ------------ ---------
  Before treatment                                                    0.696        0.706
    \<180°           44 (35.20)              58 (32.40)                            
    180°-270°        40 (32.00)              54 (30.17)                            
    \>270°           41 (32.80)              67 (37.43)                            
  After treatment                                                     2.049        0.152
    \<180°           95 (76.00)              148 (82.68)                           
    180°-270°        30 (24.00)              31 (17.32)                            
    \>270°           0 (0.00)                0 (0.00)                              
  χ^2^ value         61.141                  112.544                               
  P-value            \<0.001                 \<0.001                               

###### 

Incidence of complications (n, %).

  Factors                                     Control group (n=125)   Research group (n=179)   χ^2^ value   P-value
  ------------------------------------------- ----------------------- ------------------------ ------------ ---------
  Corneal edema                               16 (12.80)              9 (5.03)                   5.891      0.015
  Hyphema                                     3 (2.40)                1 (0.56)                   1.922      0.166
  Fibrinous exudate in the anterior chamber   2 (1.60)                3 (1.68)                   0.003      0.959
  Anterior chamber inflammation               7 (5.60)                2 (1.12)                   5.148      0.023
  In total                                    28 (22.40)              15 (8.38)                11.913       0.001
